Literatures of budget impact analysis in China and Canada: a quality assessment_Chinese Journal of Evidence-Based Medicine

Authors：

MA Aixia , QIAN Hansen , ZHANG Jiyuan , LIU Qiang ,  LI Hongchao

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, P.R.China;

Corresponding?author：

LI Hongchao, Email: lihongchao@cpu.edu.cn

Keywords：

Budget impact analysis; Quality evaluation; China; Canada

DOI：

10.7507/1672-2531.201703059

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To assess the quality of budget impact analysis in China and Canada. Methods We searched databases including PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP from inception to 1^st November, 2016, to collect studies about budget impact analysis. Two reviewers independently screened literatures, extracted data and assessed the quality of included studies. Results 27 literatures were included. The mean grades of Chinese and Canadian literatures were 3.8 and 5.5, respectively. Some Chinese studies did not explicitly clarify the research perspective. Few studies in China were conducted according to budget holders’ perspective and with a short time horizon, or examined the results using sensitivity analyses responsive to the uncertainty surrounding future market developments, or compared between current and comparator scenarios. These deficiencies were not conducive to scientific and rational decision-making. Conclusion The quality of budget impact analysis is relatively low in China. It is needed to establish uniform budget impact analysis guideline to improve quality to guide decision making.

Citation： MA Aixia, QIAN Hansen, ZHANG Jiyuan, LIU Qiang, LI Hongchao. Literatures of budget impact analysis in China and Canada: a quality assessment. Chinese Journal of Evidence-Based Medicine, 2017, 17(10): 1231-1236. doi: 10.7507/1672-2531.201703059 Copy

1.	Mauskopf A, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health, 2007, 10(5): 336-347.
2.	Sullivan SD, Mauskopf A, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health, 2014, 17(1): 5-14.
3.	劉國恩, 胡善聯, 吳久鴻. 中國藥物經濟學評價指南. 中國藥物經濟學, 2011, 6(3): 6-48.0.
4.	CADTH. Pulmonary rehabilitation for chronic obstructive pulmonary disease: clinical, economic, and budget impact analysis. CADTH Technol Overv, 2010, 1(4): e127.
5.	van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy, 2014, 12(1): 33-40.
6.	Membe SK, Coyle D, Husereau D, et al. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. CADTH Technol Overv, 2010, 1(1): 1-6.
7.	Masucci L, Goeree R. Vitamin B12 intramuscular in ections versus oral supplements: a budget impact analysis. Ont Health Technol Assess Ser, 2013, 13(24): 1-24.
8.	Theta. Frequency of Testing for Dyslipidemia: A systematic review and budget impact analysis. Ont Health Technol Assess Ser, 2014, 14(7): 1-27.
9.	Chadee A, Blackhouse G, Goeree R. Point-of-care hemoglobin A1c testing: a budget impact analysis. Ont Health Technol Assess Ser, 2014, 14(9): 1-23.
10.	Lessard M, Ouimet D, Leblanc M, et al. Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients. BMC Nephrol, 2014(1): 15-27.
11.	Pham B, Krahn M. End-of-life care interventions: an economic analysis. Ont Health Technol Assess Ser, 2014, 14(18): 1-70.
12.	Tsao NW, Lo C, Leung M , et al. A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada. Can Kidney Health Dis, 2014, 1(1): 28.
13.	Vaidya A, Stafinski T, Nardelli A, et al. Assisted reproductive technologies in alberta: an economic analysis to inform policy decision-making. Obstet Gynaecol Can, 2015, 37(12): 1122-1130.
14.	Palimaka S, Blackhouse G, Goeree R. Capsule endoscopy in the assessment of obscure gastrointestinal bleeding: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(2): 1-32.
15.	Thavorn K, Coyle D. Transient elastography and controlled attenuation parameter for diagnosing liver fibrosis and steatosis in ontario: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(19): 1-58.
16.	Babashov V, Palimaka S, Blackhouse G, et al. Magnetic resonance-guided high-intensity focused ultrasound (mrghifu) for treatment of symptomatic uterine fibroids: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(5): 1-61.
17.	Coward S, Heitman S , Clement F, et al. Funding a smoking cessation program for Crohn's disease: an economic evaluation. Am Gastroenterol, 2015, 110(3): 368-377.
18.	Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: an economic analysis. Ont Health Technol Assess Ser, 2016, 16(6): 1-51.
19.	McMartin. Left ventricular assist devices for destination therapy: a health technology assessment. Ont Health Technol Assess Ser, 2016, 16(3): 1-60.
20.	Health Quality Ontario. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: an economic analysis. Ont Health Technol Assess Ser, 2016, 16(8): 1-83.
21.	Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: An Economic Analysis. Ont Health Technol Assess Ser, 2016, 16(12): 1-34.
22.	Health Quality Ontario. Retinal prosthesis system for advanced retinitis pigmentosa: a health technology assessment. Ont Health Technol Assess Ser, 2016, 16(14): 1-63.
23.	趙琨, 肖月, 齊雪然, 等. 終末期腎病腹膜透析預算影響分析. 中國衛生經濟, 2015, 34(1): 66-69.0.
24.	張崖冰, 朱國蘭, 胡善聯, 等. 復方枸櫞酸阿爾維林治療腸易激綜合征的預算影響分析.中國衛生經濟, 2015, 34(11): 66-68.0.
25.	徐菲, 張祥華, 劉國恩. 度他雄胺治療良性前列腺增生的預算影響分析. 中國衛生經濟, 2015, 34(11): 62-65.0.
26.	林其敏, 史錄文, 韓晟, 等. 他氟前列素上市后的預算影響分析 .中國新藥雜志, 2015, 24(23): 2645-2650.0.
27.	官海靜, 王雅楠, 范長生. 維格列汀治療2型糖尿病預算影響分析. 中國醫療保險, 2016 (5): 56-59, 62.0.
28.	潘岳松, 彭曉霞. 貝復濟治療Ⅱ度燒傷的上市后藥物經濟學評價 .中國執業藥師, 2010, 7(3): 28-32.0.
29.	楊興華. 貝美前列素滴眼液上市后對預算影響的初步分析. 中國醫院用藥評價與分析, 2010, 10(11): 1015-1018.0.
30.	潘岳松, 彭曉霞. 重組牛堿性成纖維細胞生長因子治療眼角膜上皮缺損的藥物經濟學評價. 中國藥師, 2010, 13(7): 1002-1005.0.
31.	陳麗. 貝復舒滴眼液治療眼角膜缺損的有效性、安全性及經濟學評價研究. 山西醫科大學, 2010.0.
32.	Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics, 2001, 19(6): 609-621.
33.	Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics, 2008, 26(6): 477-495.
34.	錢焊森, 劉強, 馬愛霞. 藥品強制許可制度中應用藥物經濟學定量方法研究. 中國藥物評價, 2017, 34(2): 147-149.0.

1. Mauskopf A, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health, 2007, 10(5): 336-347.
2. Sullivan SD, Mauskopf A, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health, 2014, 17(1): 5-14.
3. 劉國恩, 胡善聯, 吳久鴻. 中國藥物經濟學評價指南. 中國藥物經濟學, 2011, 6(3): 6-48.0.
4. CADTH. Pulmonary rehabilitation for chronic obstructive pulmonary disease: clinical, economic, and budget impact analysis. CADTH Technol Overv, 2010, 1(4): e127.
5. van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy, 2014, 12(1): 33-40.
6. Membe SK, Coyle D, Husereau D, et al. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. CADTH Technol Overv, 2010, 1(1): 1-6.
7. Masucci L, Goeree R. Vitamin B12 intramuscular in ections versus oral supplements: a budget impact analysis. Ont Health Technol Assess Ser, 2013, 13(24): 1-24.
8. Theta. Frequency of Testing for Dyslipidemia: A systematic review and budget impact analysis. Ont Health Technol Assess Ser, 2014, 14(7): 1-27.
9. Chadee A, Blackhouse G, Goeree R. Point-of-care hemoglobin A1c testing: a budget impact analysis. Ont Health Technol Assess Ser, 2014, 14(9): 1-23.
10. Lessard M, Ouimet D, Leblanc M, et al. Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients. BMC Nephrol, 2014(1): 15-27.
11. Pham B, Krahn M. End-of-life care interventions: an economic analysis. Ont Health Technol Assess Ser, 2014, 14(18): 1-70.
12. Tsao NW, Lo C, Leung M , et al. A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada. Can Kidney Health Dis, 2014, 1(1): 28.
13. Vaidya A, Stafinski T, Nardelli A, et al. Assisted reproductive technologies in alberta: an economic analysis to inform policy decision-making. Obstet Gynaecol Can, 2015, 37(12): 1122-1130.
14. Palimaka S, Blackhouse G, Goeree R. Capsule endoscopy in the assessment of obscure gastrointestinal bleeding: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(2): 1-32.
15. Thavorn K, Coyle D. Transient elastography and controlled attenuation parameter for diagnosing liver fibrosis and steatosis in ontario: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(19): 1-58.
16. Babashov V, Palimaka S, Blackhouse G, et al. Magnetic resonance-guided high-intensity focused ultrasound (mrghifu) for treatment of symptomatic uterine fibroids: an economic analysis. Ont Health Technol Assess Ser, 2015, 15(5): 1-61.
17. Coward S, Heitman S , Clement F, et al. Funding a smoking cessation program for Crohn's disease: an economic evaluation. Am Gastroenterol, 2015, 110(3): 368-377.
18. Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: an economic analysis. Ont Health Technol Assess Ser, 2016, 16(6): 1-51.
19. McMartin. Left ventricular assist devices for destination therapy: a health technology assessment. Ont Health Technol Assess Ser, 2016, 16(3): 1-60.
20. Health Quality Ontario. Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: an economic analysis. Ont Health Technol Assess Ser, 2016, 16(8): 1-83.
21. Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: An Economic Analysis. Ont Health Technol Assess Ser, 2016, 16(12): 1-34.
22. Health Quality Ontario. Retinal prosthesis system for advanced retinitis pigmentosa: a health technology assessment. Ont Health Technol Assess Ser, 2016, 16(14): 1-63.
23. 趙琨, 肖月, 齊雪然, 等. 終末期腎病腹膜透析預算影響分析. 中國衛生經濟, 2015, 34(1): 66-69.0.
24. 張崖冰, 朱國蘭, 胡善聯, 等. 復方枸櫞酸阿爾維林治療腸易激綜合征的預算影響分析.中國衛生經濟, 2015, 34(11): 66-68.0.
25. 徐菲, 張祥華, 劉國恩. 度他雄胺治療良性前列腺增生的預算影響分析. 中國衛生經濟, 2015, 34(11): 62-65.0.
26. 林其敏, 史錄文, 韓晟, 等. 他氟前列素上市后的預算影響分析 .中國新藥雜志, 2015, 24(23): 2645-2650.0.
27. 官海靜, 王雅楠, 范長生. 維格列汀治療2型糖尿病預算影響分析. 中國醫療保險, 2016 (5): 56-59, 62.0.
28. 潘岳松, 彭曉霞. 貝復濟治療Ⅱ度燒傷的上市后藥物經濟學評價 .中國執業藥師, 2010, 7(3): 28-32.0.
29. 楊興華. 貝美前列素滴眼液上市后對預算影響的初步分析. 中國醫院用藥評價與分析, 2010, 10(11): 1015-1018.0.
30. 潘岳松, 彭曉霞. 重組牛堿性成纖維細胞生長因子治療眼角膜上皮缺損的藥物經濟學評價. 中國藥師, 2010, 13(7): 1002-1005.0.
31. 陳麗. 貝復舒滴眼液治療眼角膜缺損的有效性、安全性及經濟學評價研究. 山西醫科大學, 2010.0.
32. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics, 2001, 19(6): 609-621.
33. Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics, 2008, 26(6): 477-495.
34. 錢焊森, 劉強, 馬愛霞. 藥品強制許可制度中應用藥物經濟學定量方法研究. 中國藥物評價, 2017, 34(2): 147-149.0.

Chinese Journal of Evidence-Based Medicine

Literatures of budget impact analysis in China and Canada: a quality assessment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content